Condition: T-cell Acute Lymphoblastic Leukemia · T-cell Lymphoma · Mixed Phenotype Acute Leukemia · Sponsor: St. Jude Children's Research Hospital
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end of induction MRD-negative rate is higher in patients with ETP or near-ETP ALL treated with venetoclax compared to similar patients treated with 4-drug induction on AALL1231. Secondary Objectives * To assess the event free and overall survival of patients treated with this therapy. * To compare grade 4 toxicities, event-free survival (EFS) and overall survival (OS) of patients treated with this therapy in induction and reinduction to toxicities of similar patients treated on TOT17.
This description comes directly from the study's public registry record.
Seth E. Karol, MD, MSCI · 888-226-4343 · referralinfo@stjude.org
Always discuss trial participation with your own doctor first.
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Novant Health Presbyterian Hemby Children's Hospital | Charlotte, North Carolina, United States | Recruiting |
| Saint Francis Children's Hospital | Tulsa, Oklahoma, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06390319